300832.SZ
新产业
SZSE · Healthcare · C 制造业 · CN
CNY 51.47
−0.77%Year over year
Reported trailing growth
- Revenue
- -1.3%
- EBITDA
- —
- EBIT
- -10.6%
- EPS
- -11.7%
- Free cash flow
- +101.7%
- Operating cash flow
- +67.3%
Forward estimates
Based on analyst estimates
- Revenue
- +19.1%
- EBITDA
- +21.3%
- EPS
- +23.3%
Three-year CAGR
- Revenue
- +14.5%
- EBITDA
- +9.0%
- EBIT
- +7.8%
- Net income
- +6.9%
- EPS
- +6.8%
- Free cash flow
- +29.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026